title: [Research status on targeted therapy for squamous cell lung cancer].
abstract: With the research of driver mutations, targeted therapy for lung cancer has made a great progress. Compared with lung adenocarcinoma, treatment of squamous cell lung cancer (SCC) has been far behind. While targeted therapies have improved outcomes for patients with lung adenocarcinoma, such as EGFR-TKIs, EML4-ALK inhibitors, molecularly targeted drugs are poorly active for SCC. SCC currently lacks therapeutically exploitable genetic alterations. These observations emphasize the need for new driver mutations and "druggable" targets in SCC patients. Combining with the research in recent years, this review will discuss the research status in targeted therapy for SCC.
authors.affiliation: Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Yuan
authors.forename: Shun
authors.initials: S
authors.lastname: Lu
mesh_terms: D000818:Animals; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000628:therapy*